CD36 and prostate cancer: Interestingly, Firlej et al. also suggested that binding of CD36 to TSP-1 promotes prostate cancer cell migration and inhibits angiogenesis; however, the consequent result is increased TME hypoxia, and this hypoxic environment in turn induces TSP-1 to promote tumor cell invasion [88].